Naporafenib
Naporafenib (LXH254) is a potent, selective, orally active, type II BRAF and CRAF inhibitor, with IC50 values of 0.072 and 0.21 nM against CRAF and BRAF, respectively[1][2].
Product Specifications
CAS Number
[1800398-38-2]
Product Name Alternative
LXH254
UNSPSC
12352005
Hazard Statement
H302
Target
Bcr-Abl; p38 MAPK; Raf
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LXH254.html
Purity
99.90
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=CC=C(NC(C2=CC(C(F)(F)F)=NC=C2)=O)C=C1C3=CC(N4CCOCC4)=NC(OCCO)=C3
Molecular Formula
C25H25F3N4O4
Molecular Weight
502.49
Precautions
H302
References & Citations
[1]CAPONIGRO, Giordano, et al. THERAPEUTIC COMBINATIONS COMPRISING A RAF INHIBITOR AND A ERK INHIBITOR. WO 2018051306 A1 20180322|[2]Kelli-Ann Monaco, et al. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors. Clin Cancer Res. 2021 Apr 1;27 (7) :2061-2073.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Abl; B-Raf; C-Raf; p38α
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
